A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy. (2023)
- Record Type:
- Journal Article
- Title:
- A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy. (2023)
- Main Title:
- A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy
- Authors:
- Nakai, Masahiro
Kai, Yoshiro
Suzuki, Kentaro
Matsuda, Masayuki
Kikukawa, Shoma
Masuda, Hiroyuki
Soga, Masahiro
Ueda, Takeshi
Yoshimura, Atsushi
Takano, Masato
Hontsu, Shigeto
Uno, Kenji
Muro, Shigeo - Abstract:
- Abstract: Although immune checkpoint inhibitors (ICIs) can be used for lung cancer treatment, the activated immune response may cause immune-related adverse effects (irAEs). We present here a case of cytomegalovirus (CMV) enterocolitis during steroid therapy for an irAE. A 70-year-old man diagnosed with small-cell lung carcinoma (limited disease) received radiotherapy plus two chemotherapy cycles of cisplatin and etoposide. The tumor exhibited complete response but recurred after 3 years. After treatment with two cycles of carboplatin, etoposide, and atezolizumab, an inhibitors of programmed cell death receptor-1, he was switched to atezolizumab every 3 weeks for maintenance therapy. Diarrhea occurred after nine atezolizumab doses. With a strong suspicion of ICI-induced colitis, we administered methylprednisolone 500 mg for 3 days, followed by oral prednisolone 40 mg/day. Total colonoscopy during the treatment revealed mucosal inflammation of the total colon, suggesting immune-related colitis. Biopsies from the ulceration revealed crypt abscess with highly infiltrative plasma cells and lymphocytes. Furthermore, immunohistochemical staining showed positivity for CMV. With no improvement in watery diarrhea, the prednisolone dose was increased to 80 mg/day on the 11th day, and ganciclovir was additionally administered twice daily on the 26th day. On the 28th day, the patient had abdominal pain, and abdominal computed tomography revealed free air, resulting in the diagnosis ofAbstract: Although immune checkpoint inhibitors (ICIs) can be used for lung cancer treatment, the activated immune response may cause immune-related adverse effects (irAEs). We present here a case of cytomegalovirus (CMV) enterocolitis during steroid therapy for an irAE. A 70-year-old man diagnosed with small-cell lung carcinoma (limited disease) received radiotherapy plus two chemotherapy cycles of cisplatin and etoposide. The tumor exhibited complete response but recurred after 3 years. After treatment with two cycles of carboplatin, etoposide, and atezolizumab, an inhibitors of programmed cell death receptor-1, he was switched to atezolizumab every 3 weeks for maintenance therapy. Diarrhea occurred after nine atezolizumab doses. With a strong suspicion of ICI-induced colitis, we administered methylprednisolone 500 mg for 3 days, followed by oral prednisolone 40 mg/day. Total colonoscopy during the treatment revealed mucosal inflammation of the total colon, suggesting immune-related colitis. Biopsies from the ulceration revealed crypt abscess with highly infiltrative plasma cells and lymphocytes. Furthermore, immunohistochemical staining showed positivity for CMV. With no improvement in watery diarrhea, the prednisolone dose was increased to 80 mg/day on the 11th day, and ganciclovir was additionally administered twice daily on the 26th day. On the 28th day, the patient had abdominal pain, and abdominal computed tomography revealed free air, resulting in the diagnosis of colon perforation. He underwent subtotal colectomy followed by ileostomy as emergency surgery. A colon specimen revealed colitis with CMV infection. We describe colon perforation in a patient with CMV enterocolitis complicated by refractory immune-related colitis. … (more)
- Is Part Of:
- Respiratory medicine case reports. Volume 41(2023)
- Journal:
- Respiratory medicine case reports
- Issue:
- Volume 41(2023)
- Issue Display:
- Volume 41, Issue 2023 (2023)
- Year:
- 2023
- Volume:
- 41
- Issue:
- 2023
- Issue Sort Value:
- 2023-0041-2023-0000
- Page Start:
- Page End:
- Publication Date:
- 2023
- Subjects:
- Atezolizumab -- Colitis -- Cytomegalovirus -- Immune-related adverse event
AIDS Acquired immunodeficiency syndrome -- ICI Immune checkpoint inhibitors -- CMV Cytomegalovirus
Respiratory organs -- Diseases -- Periodicals
Chest -- Diseases -- Periodicals
Respiratory Tract Diseases -- Periodicals
Respiratory System -- Periodicals
Chest -- Diseases
Respiratory organs -- Diseases
Electronic journals
Periodicals
616.2 - Journal URLs:
- http://www.sciencedirect.com/science/journal/22130071 ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/respiratory-medicine-case-reports/ ↗ - DOI:
- 10.1016/j.rmcr.2022.101794 ↗
- Languages:
- English
- ISSNs:
- 2213-0071
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25236.xml